A phase 2 trial evaluates the combination of anlotinib and toripalimab in patients with advanced bone and soft tissue sarcomas, including ultra-rare variants. This multicenter study contributes to understanding treatment options for these challenging conditions.
anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra rare sarcomas a multicenter single arm phase 2 trial
Original title: “Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial.”